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Aim: To record ocular vascular events following injections of vascular endothelium growth 
factor (VEGF) antagonists.
Methods: Collaborative multicenter case series (48 cases), literature reviews (32 cases), and 
reports to the FDA (64 cases) of patients that had vascular occlusions during anti-VEGF therapy 
were collected and analyzed.
Results: A total of 144 cases of ocular vascular events were identified, with these diagnosed 
a median of 15 days after anti-VEGF injection. The majority of patients had pre-existing risk 
factors for cardiovascular events and nine patients had a prior history of glaucoma. Mean 
visual acuity dropped by 6.4 lines with severe visual loss after injection to NLP (five eyes), 
LP (six eyes), and HM (two eyes). The overall risk of ocular vascular events following a 
VEGF antagonist injection was 0.108% in the general population and 2.61% in the diabetic 
population. Mean retinal arterial constriction after intravitreal bevacizumab in 13 eyes was 
21% (standard deviation = 27%), and mean retinal venous constriction was 8% (standard 
deviation = 30%).
Conclusion: Ocular vascular events are rare during anti-VEGF therapy, but can lead to severe 
visual loss and may be caused by a number of factors including the vasoconstrictor effect of the 
drug, a post-injection rise of intraocular pressure, patient stress as a result of the procedure, and 
the patient’s natural history of underlying ocular or systemic diseases. The diabetic population 
appears to have a tendency towards ocular vascular occlusions.
Keywords: Bevacizumab, retinal artery occlusion, retinal vein occlusion, retinal capillary 
occlusion, ranibizumab
Introduction
Vascular endothelial growth factor (VEGF) has vasodilatory effects so is used by 
vascular surgeons to treat ischemic diseases,1 and intravitreal VEGF antagonists are 
now being used by ophthalmologists to treat various ischemic retinal disorders.2,3 
Several studies report that fluorescein angiographic findings are absent following the 
administration of intravitreal bevacizumab or ranibizumab.4–9 Preliminary case series 
reported by some researchers suggest the possibility of a temporal link between these 
injections and subsequent retinal vascular events.10–21 In the current study additional 
data that was contributed by various collaborators and supplemented by the literature22–44 
is presented to further analyze the possible relationship between anti-VEGF injections 
and ocular vascular accidents. Additionally, the current study provides information 
regarding the characterization of patients developing ocular vascular complications 
after intravitreal injections of anti-VEGF drugs.
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Methods
The current study is a retrospective survey among members of 
the American Society of Retinal Specialists who were invited 
to contribute a detailed protocol of cases that had vascular 
occlusions (central retinal artery occlusion [CRAO], branch 
retinal artery occlusion [BRAO], capillary occlusion, central 
retinal vein occlusion [CRVO], branch retinal vein occlusion 
[BRVO], anterior ischemic optic neuropathy [AION], and 
ocular ischemic syndrome) following anti-VEGF therapy. 
This research was approved by the Institutional Research 
Board (Rafic Hariri University Hospital, an affiliate of the 
American University of Beirut). Each center received Ethical 
Committee approval for the use of anti-VEGF for specific use 
and data analyses. The data collected included risk factors for 
vascular occlusion (carotid disease, coronary artery disease, 
systemic hypertension, diabetes mellitus, migraine, smoking, 
and glaucoma), the intraocular pressure on discharge, and 
the time period from intravitreal injection to detection of the 
vascular event. The total number of injections per investiga-
tor was also recorded.
A 14-month prospective study was also performed at 
Mansoura University using intravitreal bevacizumab. This 
included 42 patients, 33 of whom had proliferative diabetic 
retinopathy, seven with age-related macular degeneration, 
and two with central retinal vein occlusion. The study 
was approved by the Ethical Committee of Mansoura 
University.
Additionally, all studies in the literature regarding treat-
ments with ranibizumab, bevacizumab, pegaptanib, and 
aflibercept as listed in PubMed and Scopus prior to August 
2011 were searched for reports of adverse effects. As well as 
this, detailed reports of adverse effects of anti-VEGF medi-
cations sent to the FDA prior to April 2011 were retrieved 
via patientsville.com (for reports submitted from 2006 to 
2009) and eHealthme.com (for reports submitted from 2010 
to 2011), and retinal vascular events were selected for the 
current study.
Digital fundus photography and computerized deter-
mination of retinal trunk vessel diameters were performed 
using the previously described software.3,45,46 For each case 
the pre- and post-anti-VEGF treatment fundus photographs 
were analyzed using custom computer software. For each 
case a grader (PKK) chose at least two artery segments 
and two vein segments that were deemed the most suitable 
for analysis based on image quality, contrast, straightness 
of the vessel, absence of branching, and absence of vessel 
crossings. Images of these vessel segments taken before 
and after   anti-VEGF treatment were analyzed for each case. 
Images were considered non-gradable if the image was of 
poor   quality (low contrast), as judged by the grader. When 
  necessary, images were calibrated by scaling them so that 
they were of equal size. Results were presented as the relative 
change in vessel diameter following anti-VEGF treatment.
Results
A total of 144 cases were available for this study, which 
included 32 cases retrieved from the literature, 64 reports 
to the Food and Drug Administration (FDA), and 48 cases 
contributed from 22 centers across Africa, America, Asia, 
and Europe (Tables 1 and 2). Eight of these cases were part 
of a prospective study at Mansoura University (Mansoura 
City, Egypt) of 42 patients treated with intravitreal beva-
cizumab (33 patients with advanced proliferative diabetic 
retinopathy, seven with choroidal neovascularization, and 
two with central retinal vein occlusion). From 1665 reports of 
adverse effects following treatment with ranibizumab, 7167 
reports of adverse effects following treatment with bevaci-
zumab, 355 reports of adverse effects following treatment 
with pegaptanib, and 74 reports of adverse effects following 
treatment with aflibercept (VEGF Trap), the current study 
collected data on twelve ranibizumab-, 28 bevacizumab-, and 
six pegaptanib-related retinal vascular events.
Overall, 30 received ranibizumab, 9 pegaptanib and 106 
bevacizumab (of which 13 received systemic bevacizumab, 
one received intracameral bevacizumab, one received 
0.625 mg intravitreal bevacizumab, six received 2.5 mg 
intravitreal bevacizumab, and 55 received 1.25 mg intrav-
itreal bevacizumab). The patient’s gender was not always 
specified, but of those patients for whom this was specified 
there were 53 males and 55 females. In 95 patients, the 
median age was 67 (range = 0–95 years; mean = 64.5 years). 
Vascular events were diagnosed a median of 15 days after 
treatment (n = 56; range = 0–60 days). The median number 
of prior injections was one (range = 0–34). The right eye 
was involved in 30 patients, and the left eye in 28 patients 
(five patients had bilateral events, while the side was not 
specified for the remainder).
A majority of patients had preexisting risk factors for 
cardiovascular events. More specifically, diabetes mellitus 
was documented in a total of 44 patients. There were 37 
diabetic patients in the combined group of 80 patients from 
the collaborative study and the literature review, ie, 46.3% 
of the combined group had diabetes mellitus. Other systemic 
disorders of the whole series included systemic   hypertension 
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in 31 patients, coronary heart disease in 16, and carotid 
artery disease in eight. Moreover, nine patients had a prior 
history of glaucoma. Mean initial intraocular pressure was 
15.5 mm Hg (range = 7–24 mm Hg), and on discharge this was 
21.5 mm Hg (range = 11–50 mm Hg) (n = 32). Paracentesis 
was performed in only three cases after the injection to reverse 
post-injection ocular hypertension and to facilitate retinal per-
fusion as assessed by indirect ophthalmoscopy (two eyes had 
neovascular glaucoma, and one eye had central retinal artery 
occlusion at a post-injection pressure of 21 mm Hg).
The major ocular conditions under therapy included 
diabetic retinopathy in 39 patients (21 with proliferative 
retinopathy and twelve with background retinopathy), wet 
age-related macular degeneration in 25, and retinal venous 
occlusion in 18 (13 central and five branch varieties). The 
ocular vascular events registered were ocular vascular occlu-
sions (of an unspecified type in 30 cases), ipsilateral central 
retinal artery occlusion (19 cases), contralateral central retinal 
artery occlusion (one case), branch retinal artery occlusion 
(four cases), unspecified retinal artery occlusion (14 cases), 
ophthalmic artery occlusion (two cases), choroidal ischemia 
(one case), retinal capillary occlusion (31 cases, 19 of which 
were causing macular ischemia), central retinal vein occlu-
sion (three cases), branch retinal vein occlusion (four cases), 
unspecified retinal vein occlusion (twelve cases), retinal 
artery spasm (two cases), anterior ischemic optic neuropathy 
(16 cases), ischemic optic neuropathy (four cases), and one 
case of vision loss of unspecified origin (Tables 1 and 2).
The median follow-up time in 48 patients was 3 months 
(average = 8 months; range = 1–36 months). Mean visual 
acuity (log Mar) dropped by 6.4 lines from 0.85 (20/142; 
median = 0.7) to 1.49 (20/618; median = 1.0) (Student’s 
t-test n = 62; P = 0.0002). 40 eyes lost vision, ten eyes main-
tained vision, and 15 eyes gained vision at the last carried 
  examination. Severe visual loss after injection to no light 
perception (NLP) occurred in five eyes, light perception 
(LP) in six eyes, and hand motion (HM) in three eyes.
Ocular vascular events occurred during anti-VEGF 
therapy in eight of 42 of patients (19.0%) in this selective 
prospective study. Overall in 26 centers, 55 ocular vascu-
lar events were reported among a total of 51,152 patients 
(0.108%) that received intravitreal anti-VEGF therapy 
(Tables 1 and 2). Eight ocular vascular events were reported 
in five centers among a total of 5340 patients (0.149%) that 
received intravitreal bevacizumab therapy. In the subset of 
the population who were diabetic, 15 ocular vascular events 
were reported in four centers from a total of 575 patients 
(2.61%; Tables 1 and 2). In one center, two cases of retinal 
vascular occlusions followed intravitreal VEGF antagonists 
from a total of 300 retinovascular occlusion cases exam-
ined. In a double blind randomized prospective study, two 
patients (2%) developed retinovascular events among 102 
diabetics with macular edema treated with intravitreal ranibi-
zumab, while there were no events reported in the control   
group.30 Terui et al37 described the occurrence of capillary 
nonperfusion in four out of 58 eyes (6.9%) with branch retinal 
vein occlusion 1 month after intravitreal bevacizumab (note 
that this was minimal in three eyes and marked in one); it 
is unknown if this is related to the injection or part of the 
natural history of the ocular disease.
Retinal vasoconstriction was observed after both beva-
cizumab and ranibizumab injections. More specifically, 
vasoconstriction analyses were available in 13 of the submit-
ted 20 eyes (seven eyes did not meet the requirements for a 
paired comparison; Table 3). Vasoconstriction was measured 
between 7 and 30 days (median = 14 days) after injection 
of bevacizumab (1.25 mg) in 13 eyes. Mean retinal arterial 
constriction was 21% (standard deviation = 27%) and mean 
venous constriction was 8% (standard deviation = 30%). 
Four cases had prominent retinal arterial vasoconstriction of 
78%, 57%, 54%, and 28%, while a fifth eye had 33% retinal 
venous constriction. Vasoconstriction was also measured 
in one eye that had intravitreal ranibizumab (0.5 mg), with 
42% retinal arterial constriction and 16% retinal venous 
constriction reported.
Discussion
The adverse events associated with systemic bevacizumab 
include hypertension, proteinuria, and thromboembolism.44,47 
Mourad et al used intravital video microscopy to measure der-
mal capillary densities in the dorsum of the fingers of patients 
receiving systemic bevacizumab and showed endothelial dys-
function and rarefaction by laser Doppler flowmetry.48 The 
ocular vascular effects of VEGF antagonists are still unclear. 
Costa et al evaluated the safety of intravitreal bevacizumab 
injections for the management of macular edema due to 
ischemic central or hemicentral retinal vein occlusion, with 
no complications noted at the 25-week follow-up in seven 
patients.49 Neubauer et al tried to assess peripheral perfusion 
before and after intravitreal bevacizumab and described a 
significant improvement in retinal perfusion post injection 
in 19 patients with nonproliferative diabetic macular edema.9 
Chung et al found no visual improvement in eyes with dia-
betic macular ischemia after intravitreal bevacizumab, and 
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Table 1 Collaborative and literature review of 106 cases of ocular vascular complications of the VEGF antagonist bevacizumab:   
clinical profile
Case N./ 
sex/age
Ocular vascular  
event after
Dose used (mL) Paracentesis IOP at  
discharge  
post injection
Prior IOP Glaucoma Primary eye  
disease
Interval injection  
to detection  
of vascular 
occlusion (days)
N. prior  
injections
OD or OS Visual acuity  
prior to vascular 
event (log MAR)
Visual acuity  
after vascular  
event  
(log MAR)
Follow up  
after ocular  
event  
(months)
Systemic disease and risk of the  
vascular event per submitting  
author (new cases per total 
number of injected patients)
Arterial occlusion
1/F/60 CRAO Bevacizumab 2.5 mg No 30 15 No Ischemic CRVO/  
PDR/serous  
macular elevation
5 1 OD CF3m (1.6) 20/60 (0.5) 4 HTN
DM
carotid stenosis
1/19,158
2/F/74 CRAO Bevacizumab 1.25 mg No NA 10 No Ischemic CRVO/  
serous macular  
elevation
14 1 OD CF0.3m (2.5) CF0.3m (2.5) 1 Smoker 1/19,158
3/F/95 CRAO Bevacizumab 1.25 mg No NA 7 No AMD 28 4 OD 20/50 (0.4) LP (3.3) 5 HTN
CAD 1/19,158
4/M/49 CRAO Bevacizumab 1.25 mg Yes 21 before tap 14 No PDR/DM 0 1 OS 20/160 (0.9) NLP (3.6) DM 1/19,158
5/F/47 CRAO Bevacizumab 1.25 mg No 14 16 No PDR/vitreous  
hemorrhage
45 1 OD 20/200 (1) HM (3) DM
1/2,000
6/M/70 CRAO Bevacizumab 1.25 mg No Nl Nl No CRVO 30 1 NA 20/200 (1) CF0.3m (2.5) HTN
1/2,400 bevacizumab
7/F/56 CRAO Bevacizumab 1.25 mg No Nl Nl No CRVO 30 1 NA 20/80 (0.6) HM (3) None
1/2,400 bevacizumab
8/F/60 CRAO Bevacizumab 2.5 mg No NA 12 Yes CRVO 14 0 OD 20/20 (0.0) HM (3) 6
9/M/73 CRAO Bevacizumab 1.25 mg No 16 17 No AMD 15 1 OD 20/100 (0.7) 20/400 (1.3) 15 HTN
Smoker
1/6,478 anti-VEGF
10/F/72 CRAO Bevacizumab 1.25 mg No 19 20 No AMD 10 1 OD 20/160 (0.9) 20/250 (1.1) 18 HTN
Smoker
CAD
1/6,478 anti-VEGF
11/74/F CRAO Bevacizumab 1.25 mg No ,25 ,25 No DM 2 3 NA CF (1.6) NLP (3.6) DM/CAD
12/52/F CRAO Bevacizumab 1.25 mg No 20 mmHg 20 mmHg Yes NVG 1 1 NA 20/200 (1) NLP (3.6) DM/HTN
1331 CRAO Bevacizumab NA NA NA NA NA NA NA 20/1000 (1.7) LP (3.3) 1/400 bevacizumab
14/F/6022 CRAO Bevacizumab1.25 mg  
intracameral
Yes 50 20 Yes PDR/NVG 30 1 OD 20/200 (1) 20/200 (1) 12r DM
1527 CRAO Bevacizumab NA NA NA NA NA 7 NA NA NA NA 1/5,228
16/M/78 Contralateral  
CRAO
Bevacizumab 1.25 mg NA NA NA NA AMD 21 0 NA CF0.3m (2.5) CF1m (2) 3 Hypercholesterolemia, CAD post  
coronary bypass 3/2,400 bevacizumab
17/M/44 BRAO Bevacizumab 1.25 mg No Nl NA No Ischemic CRVO 2 1 OD 20/125 (0.8) CF2m (1.8) 9 HTN 1/2,400 anti-VEGF
18/M/76 BRAO Bevacizumab 1.25 mg No 28 12 No AMD NA 13 OD 20/400 (1.3) 20/50 (0.4) 24 HTN
DM
CAD
Smoker
1/19,158
19/M/45 BRAO Bevacizumab  
systemic
No 16 16 No None 1 1 OS 20/100 (0.7) 20/50 (0.4) 3 HTN
cancer
20/F/5332 BRAO Bevacizumab 1.25 mg NA NA NA NA PDR 14 1 OS 20/50 (0.4) 20/600 (1.5) 1 DM
1/12 PDR patients
21/M/65 Retinal artery  
occlusion
Bevacizumab Avastin Side Effects Report: 
5096382-0
22/M/80 Retinal artery  
occlusion
Bevacizumab 2.5 mg DR DM
Avastin Side Effects Report:  
5105228-35105228-3
23/F/60 Retinal artery  
occlusion
Bevacizumab Yes Avastin Side Effects Report: 5536025-2
24/F/x Retinal artery  
occlusion
Bevacizumab  
15mg/kg q 3wk
Lung cancer on Navelbine
Avastin Side Effects Report: 5593981-4
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Table 1 Collaborative and literature review of 106 cases of ocular vascular complications of the VEGF antagonist bevacizumab:   
clinical profile
Case N./ 
sex/age
Ocular vascular  
event after
Dose used (mL) Paracentesis IOP at  
discharge  
post injection
Prior IOP Glaucoma Primary eye  
disease
Interval injection  
to detection  
of vascular 
occlusion (days)
N. prior  
injections
OD or OS Visual acuity  
prior to vascular 
event (log MAR)
Visual acuity  
after vascular  
event  
(log MAR)
Follow up  
after ocular  
event  
(months)
Systemic disease and risk of the  
vascular event per submitting  
author (new cases per total 
number of injected patients)
Arterial occlusion
1/F/60 CRAO Bevacizumab 2.5 mg No 30 15 No Ischemic CRVO/  
PDR/serous  
macular elevation
5 1 OD CF3m (1.6) 20/60 (0.5) 4 HTN
DM
carotid stenosis
1/19,158
2/F/74 CRAO Bevacizumab 1.25 mg No NA 10 No Ischemic CRVO/  
serous macular  
elevation
14 1 OD CF0.3m (2.5) CF0.3m (2.5) 1 Smoker 1/19,158
3/F/95 CRAO Bevacizumab 1.25 mg No NA 7 No AMD 28 4 OD 20/50 (0.4) LP (3.3) 5 HTN
CAD 1/19,158
4/M/49 CRAO Bevacizumab 1.25 mg Yes 21 before tap 14 No PDR/DM 0 1 OS 20/160 (0.9) NLP (3.6) DM 1/19,158
5/F/47 CRAO Bevacizumab 1.25 mg No 14 16 No PDR/vitreous  
hemorrhage
45 1 OD 20/200 (1) HM (3) DM
1/2,000
6/M/70 CRAO Bevacizumab 1.25 mg No Nl Nl No CRVO 30 1 NA 20/200 (1) CF0.3m (2.5) HTN
1/2,400 bevacizumab
7/F/56 CRAO Bevacizumab 1.25 mg No Nl Nl No CRVO 30 1 NA 20/80 (0.6) HM (3) None
1/2,400 bevacizumab
8/F/60 CRAO Bevacizumab 2.5 mg No NA 12 Yes CRVO 14 0 OD 20/20 (0.0) HM (3) 6
9/M/73 CRAO Bevacizumab 1.25 mg No 16 17 No AMD 15 1 OD 20/100 (0.7) 20/400 (1.3) 15 HTN
Smoker
1/6,478 anti-VEGF
10/F/72 CRAO Bevacizumab 1.25 mg No 19 20 No AMD 10 1 OD 20/160 (0.9) 20/250 (1.1) 18 HTN
Smoker
CAD
1/6,478 anti-VEGF
11/74/F CRAO Bevacizumab 1.25 mg No ,25 ,25 No DM 2 3 NA CF (1.6) NLP (3.6) DM/CAD
12/52/F CRAO Bevacizumab 1.25 mg No 20 mmHg 20 mmHg Yes NVG 1 1 NA 20/200 (1) NLP (3.6) DM/HTN
1331 CRAO Bevacizumab NA NA NA NA NA NA NA 20/1000 (1.7) LP (3.3) 1/400 bevacizumab
14/F/6022 CRAO Bevacizumab1.25 mg  
intracameral
Yes 50 20 Yes PDR/NVG 30 1 OD 20/200 (1) 20/200 (1) 12r DM
1527 CRAO Bevacizumab NA NA NA NA NA 7 NA NA NA NA 1/5,228
16/M/78 Contralateral  
CRAO
Bevacizumab 1.25 mg NA NA NA NA AMD 21 0 NA CF0.3m (2.5) CF1m (2) 3 Hypercholesterolemia, CAD post  
coronary bypass 3/2,400 bevacizumab
17/M/44 BRAO Bevacizumab 1.25 mg No Nl NA No Ischemic CRVO 2 1 OD 20/125 (0.8) CF2m (1.8) 9 HTN 1/2,400 anti-VEGF
18/M/76 BRAO Bevacizumab 1.25 mg No 28 12 No AMD NA 13 OD 20/400 (1.3) 20/50 (0.4) 24 HTN
DM
CAD
Smoker
1/19,158
19/M/45 BRAO Bevacizumab  
systemic
No 16 16 No None 1 1 OS 20/100 (0.7) 20/50 (0.4) 3 HTN
cancer
20/F/5332 BRAO Bevacizumab 1.25 mg NA NA NA NA PDR 14 1 OS 20/50 (0.4) 20/600 (1.5) 1 DM
1/12 PDR patients
21/M/65 Retinal artery  
occlusion
Bevacizumab Avastin Side Effects Report: 
5096382-0
22/M/80 Retinal artery  
occlusion
Bevacizumab 2.5 mg DR DM
Avastin Side Effects Report:  
5105228-35105228-3
23/F/60 Retinal artery  
occlusion
Bevacizumab Yes Avastin Side Effects Report: 5536025-2
24/F/x Retinal artery  
occlusion
Bevacizumab  
15mg/kg q 3wk
Lung cancer on Navelbine
Avastin Side Effects Report: 5593981-4
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Table 1 (Continued)
Case N./ 
sex/age
Ocular vascular  
event after
Dose used (mL) Paracentesis IOP at  
discharge  
post injection
Prior IOP Glaucoma Primary eye  
disease
Interval injection  
to detection  
of vascular 
occlusion (days)
N. prior  
injections
OD or OS Visual acuity  
prior to vascular 
event (log MAR)
Visual acuity  
after vascular  
event  
(log MAR)
Follow up  
after ocular  
event  
(months)
Systemic disease and risk of the  
vascular event per submitting  
author (new cases per total 
number of injected patients)
25/M/x Retinal artery  
occlusion
Bevacizumab 1.25 mg CME Avastin Side Effects Report: 5736856-X, 
5746319-3
26/M/44 Retinal artery  
occlusion
Bevacizumab 1.25 mg Retinal vein  
occlusion
Avastin Side Effects Report: 6237313-7, 
6237504-5, 6253539-0, 6253542-0, 
6341872-3; 6358564-7
Venous occlusion
27/M/93 CRVO Bevacizumab 1.25 mg No 29 15 Yes AMD 10 1 OD 20/60 (0.5) 20/400 (1.3) 18 HTN
CAD (stent; pacemaker)
Left carotid artery disease
1/19,158
28/M/5034 CRVO Bevacizumab systemic NA NA NA NA None 1 day after  
each cycle
NA OD 20/120 (0.8) NA Metastatic adenocarcinoma of colon  
after 2 cycles of capecitabine, oxaliplatin 
and bevacizumab
29/F/6536 CRVO-like  
picture
Bevacizumab 1.25 mg No NA NA No PDR 7 0 OD 20/400 (1.3) 20/200 (1) 9 DM
30/F/79 BRVO Bevacizumab 1.25 mg No 32 11 No AMD 55 1 OS 20/30 (0.2) 20/30 (0.2) 18 HTN
CAD 
Migraine
CVA
1/19,158
31/M/65 BRVO Bevacizumab 1.25 mg No 22 16 No PDR/ischemic DM/  
vitreous  
hemorrhage
7 0 OS CF2m (1.8) 20/200 (1) 3 HTN
DM
1/42 prospective study
32/M/63 BRVO Bevacizumab 1.25 mg No 24 16 No PDR/ischemic DM 7 0 OD CF4m (1.5) 20/80 (0.6) 3 HTN
DM
1/42 prospective study
33/premature  
baby28
Inferior retinal  
vein sheathing  
(nonperfusion)
Bevacizumab 0.625 mg NA NA NA No Retinopathy of  
prematurity
3 0 OU NA NA Retinopathy of prematurity
1/40 patients with retinopathy  
of prematurity
3439 Retinal vein  
occlusion
Bevacizumab 1.25 mg NA NA NA NA AMD NA NA NA NA NA 1/300 of wet AMD
3539 Retinal vein  
occlusion
Bevacizumab 1.2 mg NA NA NA NA AMD NA NA NA NA NA 1/300 of wet AMD
36/M/90 Retinal vein  
occlusion (ischemic)
Bevacizumab 1.25 mg HTN, CAD, dyslipidemia
Avastin Side Effects Report: 5197845-X, 
5197968-5
37/F/x Retinal vein  
occlusion (ischemic)
Bevacizumab 1.25 mg Avastin Side Effects Report: 5508336-8, 
5532270-0
38/F/x Retinal vein  
occlusion
Bevacizumab 1.25 mg DR DM
Avastin Side Effects Report: 5706126-4
39/F/27 Retinal vein  
occlusion
Bevacizumab Retinal  
neovascularization
Side Effects Report: 6054515-3
40/F/73 Retinal vein  
occlusion
Bevacizumab  
350 mg q2wk
Colon cancer on capecitabine, 
oxaliplatin
Avastin Side Effects Report: 4839872-5, 
4865570-8
41/F/x Retinal vein  
occlusion
Bevacizumab  
1000 mg q3wk
Lung cancer
Avastin Side Effects Report: 6209258-X
42/M/69 Retinal vein  
occlusion
Bevacizumab CME Avastin Side Effects Report: 6440612-7
43/M/72 Retinal vein  
occlusion
Bevacizumab CME Avastin Side Effects Report: 6440613-9
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Table 1 (Continued)
Case N./ 
sex/age
Ocular vascular  
event after
Dose used (mL) Paracentesis IOP at  
discharge  
post injection
Prior IOP Glaucoma Primary eye  
disease
Interval injection  
to detection  
of vascular 
occlusion (days)
N. prior  
injections
OD or OS Visual acuity  
prior to vascular 
event (log MAR)
Visual acuity  
after vascular  
event  
(log MAR)
Follow up  
after ocular  
event  
(months)
Systemic disease and risk of the  
vascular event per submitting  
author (new cases per total 
number of injected patients)
25/M/x Retinal artery  
occlusion
Bevacizumab 1.25 mg CME Avastin Side Effects Report: 5736856-X, 
5746319-3
26/M/44 Retinal artery  
occlusion
Bevacizumab 1.25 mg Retinal vein  
occlusion
Avastin Side Effects Report: 6237313-7, 
6237504-5, 6253539-0, 6253542-0, 
6341872-3; 6358564-7
Venous occlusion
27/M/93 CRVO Bevacizumab 1.25 mg No 29 15 Yes AMD 10 1 OD 20/60 (0.5) 20/400 (1.3) 18 HTN
CAD (stent; pacemaker)
Left carotid artery disease
1/19,158
28/M/5034 CRVO Bevacizumab systemic NA NA NA NA None 1 day after  
each cycle
NA OD 20/120 (0.8) NA Metastatic adenocarcinoma of colon  
after 2 cycles of capecitabine, oxaliplatin 
and bevacizumab
29/F/6536 CRVO-like  
picture
Bevacizumab 1.25 mg No NA NA No PDR 7 0 OD 20/400 (1.3) 20/200 (1) 9 DM
30/F/79 BRVO Bevacizumab 1.25 mg No 32 11 No AMD 55 1 OS 20/30 (0.2) 20/30 (0.2) 18 HTN
CAD 
Migraine
CVA
1/19,158
31/M/65 BRVO Bevacizumab 1.25 mg No 22 16 No PDR/ischemic DM/  
vitreous  
hemorrhage
7 0 OS CF2m (1.8) 20/200 (1) 3 HTN
DM
1/42 prospective study
32/M/63 BRVO Bevacizumab 1.25 mg No 24 16 No PDR/ischemic DM 7 0 OD CF4m (1.5) 20/80 (0.6) 3 HTN
DM
1/42 prospective study
33/premature  
baby28
Inferior retinal  
vein sheathing  
(nonperfusion)
Bevacizumab 0.625 mg NA NA NA No Retinopathy of  
prematurity
3 0 OU NA NA Retinopathy of prematurity
1/40 patients with retinopathy  
of prematurity
3439 Retinal vein  
occlusion
Bevacizumab 1.25 mg NA NA NA NA AMD NA NA NA NA NA 1/300 of wet AMD
3539 Retinal vein  
occlusion
Bevacizumab 1.2 mg NA NA NA NA AMD NA NA NA NA NA 1/300 of wet AMD
36/M/90 Retinal vein  
occlusion (ischemic)
Bevacizumab 1.25 mg HTN, CAD, dyslipidemia
Avastin Side Effects Report: 5197845-X, 
5197968-5
37/F/x Retinal vein  
occlusion (ischemic)
Bevacizumab 1.25 mg Avastin Side Effects Report: 5508336-8, 
5532270-0
38/F/x Retinal vein  
occlusion
Bevacizumab 1.25 mg DR DM
Avastin Side Effects Report: 5706126-4
39/F/27 Retinal vein  
occlusion
Bevacizumab Retinal  
neovascularization
Side Effects Report: 6054515-3
40/F/73 Retinal vein  
occlusion
Bevacizumab  
350 mg q2wk
Colon cancer on capecitabine, 
oxaliplatin
Avastin Side Effects Report: 4839872-5, 
4865570-8
41/F/x Retinal vein  
occlusion
Bevacizumab  
1000 mg q3wk
Lung cancer
Avastin Side Effects Report: 6209258-X
42/M/69 Retinal vein  
occlusion
Bevacizumab CME Avastin Side Effects Report: 6440612-7
43/M/72 Retinal vein  
occlusion
Bevacizumab CME Avastin Side Effects Report: 6440613-9
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Case N./ 
sex/age
Ocular vascular  
event after
Dose used (mL) Paracentesis IOP at  
discharge  
post injection
Prior IOP Glaucoma Primary eye  
disease
Interval injection  
to detection  
of vascular 
occlusion (days)
N. prior  
injections
OD or OS Visual acuity  
prior to vascular 
event (log MAR)
Visual acuity  
after vascular  
event  
(log MAR)
Follow up  
after ocular  
event  
(months)
Systemic disease and risk of the  
vascular event per submitting  
author (new cases per total 
number of injected patients)
Retinal vascular occlusion (unspecified)
44/M/43 Retinal vascular  
disorder
Bevacizumab 1 mg DR DM
Avastin Side Effects Report: 5959710-7
45/M/41 Retinal vascular  
disorder
Bevacizumab 1 mg DR DM
Avastin Side Effects Report: 5961890-4
46/F/x Retinal vascular  
disorder
Bevacizumab 1 mg DR DM
Avastin Side Effects Report: 6033375-0
47/M/x Retinal vascular  
disorder
Bevacizumab 1 mg maculopathy HTN
Avastin Side Effects Report: 6159169-3
48/F/x Retinal vascular  
disorder
Bevacizumab 1 mg CAD, unstable angina
Avastin Side Effects Report: 6291768-0
49/M/75 Retinal vascular  
disorder
Bevacizumab 1 mg DM DM
Avastin Side Effects Report: 6438164-01i
50/F/33 Retinal vascular  
disorder
Bevacizumab Vitreous  
hemorrhage
Avastin Side Effects Report: 5724031-4
51-59/9 cases  
above 40 years
Retinal vascular  
disorder
Bevacizumab mixed 2010 events from eHealthMe drug 
outcomes from FDA and community
Optic neuropathy
60/F/72 AION Bevacizumab 1.25 mg No NA 12 No AMD; fellow eye  
AION
7 1 OS CF2m (1.8) LP (3.3) 0.5 none 1/2,100 bevacizumab
61/F/71 AION Bevacizumab 1.25 mg No 16 20 No AMD 60 1 OS 20/70 (0.55) 20/70 (0.55) 6 HTN 1/333
62/M/51 AION Bevacizumab 1.25 mg No NA NA No AMD 15 1 OD 20/25 (0.1) 20/25 (0.1) 12r Pseudoxanthoma elasticum
63/F/38 AION Bevacizumab 1.25 mg No 21 23 Yes DM 21 0 OS 20/40 (0.3) 20/25 (0.1) 14 DM
1/150 bevacizumab
64/F/70 AION Bevacizumab 1.25 mg No Nl Nl No AMD 28 3 OD 20/60 (0.5) 20/120 (0.8) 6 None
1/500 bevacizumab
65/M/86 AION Bevacizumab 2.5 mg No No AMD 30 14 OD 20/70 (0.55) 20/100 (0.7) 12 HTN, prostate cancer, esophageal 
cancer, on amlodipine
1/6000 injection anti-VEGF
66/F/92 AION Bevacizumab 2.5 mg AMD 8 OS 20/70 (0.55) 20/100 (0.7) 48 No significant past medical history,  
on no medications
67/M/70 AION Bevacizumab 1.25 mg AMD 34 OS 20/70 (0.55) 20/200 (1.0) 6 No significant past medical history,  
on aspirin
68/M/x AION Bevacizumab 10 mg/kg Visual acuity  
reduced
Renal cancer on interferon
Avastin Side Effects Report: 5863726-9, 
5872556-3
69/F/x AION Bevacizumab  
394 mg days 1 and 15
Breast cancer on capecitabine
Avastin Side Effects Report: 5927943-1
70/F/x AION Bevacizumab 1.25 mg DR DM
Avastin Side Effects Report: 6155052-8
71/F/72 AION Bevacizumab Avastin Side Effects Report: 6367854-3
72/F/47 Optic neuropathy Bevacizumab systemic  
monthly
NA NA NA NA Glioblastoma right  
frontotemporal
2 years after  
initial injection
.20  
(monthly)
OU 20/200 (1) 
(amblyopia) OD  
20/70 (0.55) OS
LP OD (3.3) 
NLP (3.6) OS
30
73/M42 Optic neuropathy Bevacizumab systemic NA NA NA NA Glioblastoma NA 8 OU NA NA
74/F/6742 Optic neuropathy Bevacizumab systemic NA NA NA NA Glioblastoma NA 6 OS NA NA
75/F/5942 Optic neuropathy Bevacizumab systemic NA NA NA NA Glioblastoma NA 7 OU NA NA
Capillary occlusion
76/F/58 Macular ischemia 1.25 mg Bevacizumab No Nl Nl No Background DR 2 1 OD 20/60 (0.5) 20/400 (1.3) 12 DM 1/2,350 anti-VEGF
77/F/73 Macular ischemia Bevacizumab 1.25 mg No NA NA No Pre-PDR 42 0 OS 20/80 (0.6) 20/80 (0.6) 3 DM
HTN
1/53 retrospective study of BRVO  
and diabetic maculopathy
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Table 1 (Continued)
Case N./ 
sex/age
Ocular vascular  
event after
Dose used (mL) Paracentesis IOP at  
discharge  
post injection
Prior IOP Glaucoma Primary eye  
disease
Interval injection  
to detection  
of vascular 
occlusion (days)
N. prior  
injections
OD or OS Visual acuity  
prior to vascular 
event (log MAR)
Visual acuity  
after vascular  
event  
(log MAR)
Follow up  
after ocular  
event  
(months)
Systemic disease and risk of the  
vascular event per submitting  
author (new cases per total 
number of injected patients)
Retinal vascular occlusion (unspecified)
44/M/43 Retinal vascular  
disorder
Bevacizumab 1 mg DR DM
Avastin Side Effects Report: 5959710-7
45/M/41 Retinal vascular  
disorder
Bevacizumab 1 mg DR DM
Avastin Side Effects Report: 5961890-4
46/F/x Retinal vascular  
disorder
Bevacizumab 1 mg DR DM
Avastin Side Effects Report: 6033375-0
47/M/x Retinal vascular  
disorder
Bevacizumab 1 mg maculopathy HTN
Avastin Side Effects Report: 6159169-3
48/F/x Retinal vascular  
disorder
Bevacizumab 1 mg CAD, unstable angina
Avastin Side Effects Report: 6291768-0
49/M/75 Retinal vascular  
disorder
Bevacizumab 1 mg DM DM
Avastin Side Effects Report: 6438164-01i
50/F/33 Retinal vascular  
disorder
Bevacizumab Vitreous  
hemorrhage
Avastin Side Effects Report: 5724031-4
51-59/9 cases  
above 40 years
Retinal vascular  
disorder
Bevacizumab mixed 2010 events from eHealthMe drug 
outcomes from FDA and community
Optic neuropathy
60/F/72 AION Bevacizumab 1.25 mg No NA 12 No AMD; fellow eye  
AION
7 1 OS CF2m (1.8) LP (3.3) 0.5 none 1/2,100 bevacizumab
61/F/71 AION Bevacizumab 1.25 mg No 16 20 No AMD 60 1 OS 20/70 (0.55) 20/70 (0.55) 6 HTN 1/333
62/M/51 AION Bevacizumab 1.25 mg No NA NA No AMD 15 1 OD 20/25 (0.1) 20/25 (0.1) 12r Pseudoxanthoma elasticum
63/F/38 AION Bevacizumab 1.25 mg No 21 23 Yes DM 21 0 OS 20/40 (0.3) 20/25 (0.1) 14 DM
1/150 bevacizumab
64/F/70 AION Bevacizumab 1.25 mg No Nl Nl No AMD 28 3 OD 20/60 (0.5) 20/120 (0.8) 6 None
1/500 bevacizumab
65/M/86 AION Bevacizumab 2.5 mg No No AMD 30 14 OD 20/70 (0.55) 20/100 (0.7) 12 HTN, prostate cancer, esophageal 
cancer, on amlodipine
1/6000 injection anti-VEGF
66/F/92 AION Bevacizumab 2.5 mg AMD 8 OS 20/70 (0.55) 20/100 (0.7) 48 No significant past medical history,  
on no medications
67/M/70 AION Bevacizumab 1.25 mg AMD 34 OS 20/70 (0.55) 20/200 (1.0) 6 No significant past medical history,  
on aspirin
68/M/x AION Bevacizumab 10 mg/kg Visual acuity  
reduced
Renal cancer on interferon
Avastin Side Effects Report: 5863726-9, 
5872556-3
69/F/x AION Bevacizumab  
394 mg days 1 and 15
Breast cancer on capecitabine
Avastin Side Effects Report: 5927943-1
70/F/x AION Bevacizumab 1.25 mg DR DM
Avastin Side Effects Report: 6155052-8
71/F/72 AION Bevacizumab Avastin Side Effects Report: 6367854-3
72/F/47 Optic neuropathy Bevacizumab systemic  
monthly
NA NA NA NA Glioblastoma right  
frontotemporal
2 years after  
initial injection
.20  
(monthly)
OU 20/200 (1) 
(amblyopia) OD  
20/70 (0.55) OS
LP OD (3.3) 
NLP (3.6) OS
30
73/M42 Optic neuropathy Bevacizumab systemic NA NA NA NA Glioblastoma NA 8 OU NA NA
74/F/6742 Optic neuropathy Bevacizumab systemic NA NA NA NA Glioblastoma NA 6 OS NA NA
75/F/5942 Optic neuropathy Bevacizumab systemic NA NA NA NA Glioblastoma NA 7 OU NA NA
Capillary occlusion
76/F/58 Macular ischemia 1.25 mg Bevacizumab No Nl Nl No Background DR 2 1 OD 20/60 (0.5) 20/400 (1.3) 12 DM 1/2,350 anti-VEGF
77/F/73 Macular ischemia Bevacizumab 1.25 mg No NA NA No Pre-PDR 42 0 OS 20/80 (0.6) 20/80 (0.6) 3 DM
HTN
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Table 1 (Continued)
Case N./ 
sex/age
Ocular vascular  
event after
Dose used (mL) Paracentesis IOP at  
discharge  
post injection
Prior IOP Glaucoma Primary eye  
disease
Interval injection  
to detection  
of vascular 
occlusion (days)
N. prior  
injections
OD or OS Visual acuity  
prior to vascular 
event (log MAR)
Visual acuity  
after vascular  
event  
(log MAR)
Follow up  
after ocular  
event  
(months)
Systemic disease and risk of the  
vascular event per submitting  
author (new cases per total 
number of injected patients)
78/F/72 Macular ischemia Bevacizumab 1.25 mg No NA NA No BRVO 28 0 OS 20/60 (0.5) 20/80 (0.6) 2 DM
HTN
1/53 retrospective study of BRVO and 
diabetic maculopathy
79/M/66 Macular ischemia Bevacizumab 1.25 mg No 16 10 Yes CRVO/pre-PDR 4 1 OS 20/100 (0.7) 20/220 (1.04) 30 DM
1 of 1,500 anti-VEGF
80/F/3726 Macular ischemia Bevacizumab 1.25 mg NA NA NA No Vasculitis 7 1 OS 20/50 (0.4) 20/125 (0.8) 1 None
81/M/4035 Macular ischemia Bevacizumab 2.5 mg NA NA NA No PDR NA 0 OS 20/400 (1.3) 20/400 (1.3) DM
82/F/7625 Macular ischemia Bevacizumab 1.25 mg NA NA NA NA CRVO ischemic 28 1 OD 20/200 (1) 20/200 (1) 1 DM 
CVA
1/300 of retinal vascular occlusion cases
83/M/7425 Macular ischemia Bevacizumab 1.25 mg NA NA NA NA CRVO ischemic 28 2 OS 20/100 (0.7) 20/200 (1) 1 DM
MI
1/300 of retinal vascular occlusion cases
84/M/5829 Macular ischemia Bevacizumab 1.25 mg No NA NA No DM 21 0 OD 20/80 (0.6) 20/200 (1) 6 DM
85/ F/58 Macular ischemia Bevacizumab 1.25 mg No 20 14 No PDR/diffuse DM 7 0 OD 20/200 (1) 20/80 (0.6) 3 HTN
DM
1/42 prospective study
86/F/60 Macular ischemia Bevacizumab 1.25 mg No 18 14 No PDR/diffuse DM 7 0 OS 20/200 (1) 20/120 (0.8) 3 HTN
DM
1/42 prospective study
87/M/64 Macular ischemia Bevacizumab 1.25 mg No 20 16 No PDR/diffuse DM/ 
vitreous  
hemorrhage
7 0 OD CF3m (1.6) 20/80 (0.6) 3 HTN
DM
Hepatic disease
1/42 prospective study
88/F/65 Macular ischemia Bevacizumab 1.25 mg No 22 14 No PDR/diffuse DM 7 0 OD 20/120 (0.8) 20/80 (0.6) 3 DM 1/42 prospective study
89/M/64 Macular ischemia Bevacizumab 1.25 mg No 18 14 No PDR/ischemic DM 7 0 OS 20/200 (1) 20/80 (0.6) 3 HTN
DM 1/42 prospective study
90/M/52 Macular ischemia Bevacizumab 1.25 mg No 24 18 No PDR/diffuse DM 7 0 OD 20/200 (1) 20/120 (0.8) 3 DM 1/42 prospective study
91/M/70 Hemorrhagic  
macular infarction;  
worsening CRVO
Bevacizumab 1.25 mg NA NA 15 No CRVO 21 0 OS 20/100 (0.7) 20/320 (1.2) 1 None 1/2,000
92/M/6523 Conversion of  
nonischemic CRVO  
into ischemic CRVO
Bevacizumab 1.25 mg NA NA NA NA CRVO 21 1 OD 20/50 (0.4) 20/800 (1.6) 6 DM
9344 Capillary occlusion  
Cotton wool spot
Bevacizumab  
intravitreal
9437 Capillary ischemia Bevacizumab 1.25 mg No NA NA No Nonischemic 
BRVO
1 month 0 NA NA NA 1 1/37 nonischemic branch retinal vein 
occlusion
9537 Capillary ischemia Bevacizumab 1.25 mg No NA NA No Nonischemic 
BRVO
1 month 0 NA NA NA 1 1/37 nonischemic branch retinal vein 
occlusion
9637 Capillary ischemia Bevacizumab 1.25 mg No NA NA No Nonischemic 
BRVO
1 month 0 NA NA NA 1 1/37 nonischemic branch retinal vein 
occlusion
97/F/6237 Capillary ischemia Bevacizumab 1.25 mg No NA NA No Ischemic BRVO 1 month 0 OS 20/120 (0.8) 20/200 (1.0) 1 1 of 21 with ischemic BVO
9841 Retinal ischemia Bevacizumab 1.25 mg NA NA NA NA CRVO NA NA NA NA NA 1/186 total patients in 1 center  
(1/9 eyes with CRVO, 0/173 eyes  
with AMD)
99/M/66 Capillary occlusion  
Cotton wool spot
Bevacizumab 1.25 mg No 14 24 No AMD 30 1 OS 20/200 (1) 20/200 (1) 36 Gout 1/2,500
100/F/74 Capillary occlusion  
Cotton wool spot
Bevacizumab 1.25 mg No 11 23 No Idiopathic foveal  
telangiectasia
60 1 OS 20/80 (0.6) 20/70 (0.55) 36 HTN 1/2,500
101/F/27 Capillary occlusion Bevacizumab 1.25 mg No NA NA No Retinal vasculitis 14 1 OU 20/20 (0) 20/20 (0) 1 No 1/19,158
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Case N./ 
sex/age
Ocular vascular  
event after
Dose used (mL) Paracentesis IOP at  
discharge  
post injection
Prior IOP Glaucoma Primary eye  
disease
Interval injection  
to detection  
of vascular 
occlusion (days)
N. prior  
injections
OD or OS Visual acuity  
prior to vascular 
event (log MAR)
Visual acuity  
after vascular  
event  
(log MAR)
Follow up  
after ocular  
event  
(months)
Systemic disease and risk of the  
vascular event per submitting  
author (new cases per total 
number of injected patients)
78/F/72 Macular ischemia Bevacizumab 1.25 mg No NA NA No BRVO 28 0 OS 20/60 (0.5) 20/80 (0.6) 2 DM
HTN
1/53 retrospective study of BRVO and 
diabetic maculopathy
79/M/66 Macular ischemia Bevacizumab 1.25 mg No 16 10 Yes CRVO/pre-PDR 4 1 OS 20/100 (0.7) 20/220 (1.04) 30 DM
1 of 1,500 anti-VEGF
80/F/3726 Macular ischemia Bevacizumab 1.25 mg NA NA NA No Vasculitis 7 1 OS 20/50 (0.4) 20/125 (0.8) 1 None
81/M/4035 Macular ischemia Bevacizumab 2.5 mg NA NA NA No PDR NA 0 OS 20/400 (1.3) 20/400 (1.3) DM
82/F/7625 Macular ischemia Bevacizumab 1.25 mg NA NA NA NA CRVO ischemic 28 1 OD 20/200 (1) 20/200 (1) 1 DM 
CVA
1/300 of retinal vascular occlusion cases
83/M/7425 Macular ischemia Bevacizumab 1.25 mg NA NA NA NA CRVO ischemic 28 2 OS 20/100 (0.7) 20/200 (1) 1 DM
MI
1/300 of retinal vascular occlusion cases
84/M/5829 Macular ischemia Bevacizumab 1.25 mg No NA NA No DM 21 0 OD 20/80 (0.6) 20/200 (1) 6 DM
85/ F/58 Macular ischemia Bevacizumab 1.25 mg No 20 14 No PDR/diffuse DM 7 0 OD 20/200 (1) 20/80 (0.6) 3 HTN
DM
1/42 prospective study
86/F/60 Macular ischemia Bevacizumab 1.25 mg No 18 14 No PDR/diffuse DM 7 0 OS 20/200 (1) 20/120 (0.8) 3 HTN
DM
1/42 prospective study
87/M/64 Macular ischemia Bevacizumab 1.25 mg No 20 16 No PDR/diffuse DM/ 
vitreous  
hemorrhage
7 0 OD CF3m (1.6) 20/80 (0.6) 3 HTN
DM
Hepatic disease
1/42 prospective study
88/F/65 Macular ischemia Bevacizumab 1.25 mg No 22 14 No PDR/diffuse DM 7 0 OD 20/120 (0.8) 20/80 (0.6) 3 DM 1/42 prospective study
89/M/64 Macular ischemia Bevacizumab 1.25 mg No 18 14 No PDR/ischemic DM 7 0 OS 20/200 (1) 20/80 (0.6) 3 HTN
DM 1/42 prospective study
90/M/52 Macular ischemia Bevacizumab 1.25 mg No 24 18 No PDR/diffuse DM 7 0 OD 20/200 (1) 20/120 (0.8) 3 DM 1/42 prospective study
91/M/70 Hemorrhagic  
macular infarction;  
worsening CRVO
Bevacizumab 1.25 mg NA NA 15 No CRVO 21 0 OS 20/100 (0.7) 20/320 (1.2) 1 None 1/2,000
92/M/6523 Conversion of  
nonischemic CRVO  
into ischemic CRVO
Bevacizumab 1.25 mg NA NA NA NA CRVO 21 1 OD 20/50 (0.4) 20/800 (1.6) 6 DM
9344 Capillary occlusion  
Cotton wool spot
Bevacizumab  
intravitreal
9437 Capillary ischemia Bevacizumab 1.25 mg No NA NA No Nonischemic 
BRVO
1 month 0 NA NA NA 1 1/37 nonischemic branch retinal vein 
occlusion
9537 Capillary ischemia Bevacizumab 1.25 mg No NA NA No Nonischemic 
BRVO
1 month 0 NA NA NA 1 1/37 nonischemic branch retinal vein 
occlusion
9637 Capillary ischemia Bevacizumab 1.25 mg No NA NA No Nonischemic 
BRVO
1 month 0 NA NA NA 1 1/37 nonischemic branch retinal vein 
occlusion
97/F/6237 Capillary ischemia Bevacizumab 1.25 mg No NA NA No Ischemic BRVO 1 month 0 OS 20/120 (0.8) 20/200 (1.0) 1 1 of 21 with ischemic BVO
9841 Retinal ischemia Bevacizumab 1.25 mg NA NA NA NA CRVO NA NA NA NA NA 1/186 total patients in 1 center  
(1/9 eyes with CRVO, 0/173 eyes  
with AMD)
99/M/66 Capillary occlusion  
Cotton wool spot
Bevacizumab 1.25 mg No 14 24 No AMD 30 1 OS 20/200 (1) 20/200 (1) 36 Gout 1/2,500
100/F/74 Capillary occlusion  
Cotton wool spot
Bevacizumab 1.25 mg No 11 23 No Idiopathic foveal  
telangiectasia
60 1 OS 20/80 (0.6) 20/70 (0.55) 36 HTN 1/2,500
101/F/27 Capillary occlusion Bevacizumab 1.25 mg No NA NA No Retinal vasculitis 14 1 OU 20/20 (0) 20/20 (0) 1 No 1/19,158
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Case N./ 
sex/age
Ocular vascular  
event after
Dose used (mL) Paracentesis IOP at  
discharge  
post injection
Prior IOP Glaucoma Primary eye  
disease
Interval injection  
to detection  
of vascular 
occlusion (days)
N. prior  
injections
OD or OS Visual acuity  
prior to vascular 
event (log MAR)
Visual acuity  
after vascular  
event  
(log MAR)
Follow up  
after ocular  
event  
(months)
Systemic disease and risk of the  
vascular event per submitting  
author (new cases per total 
number of injected patients)
Miscellaneous
102/M/55 Ophthalmic artery  
occlusion
Bevacizumab 1.25 mg Yes NA NA Yes PDR/NVG 3 1 OS 20/200 (1) NLP (3.6) 3 DM, carotid artery occlusion  
1/256 bevacizumab
103/F/40 Choroidal infarction, 
HTN retinopathy
Bevacizumab  
15 mg/kg q3wk
Glioma, HTN Avastin Side Effects 
Report: 4969093-7
10424 Visual loss Bevacizumab NA NA NA NA PDR 21 NA NA NA NA DM
105/M/78 Retinal artery  
spasm
Bevacizumab  
5 mg/kg q2wk
Colon cancer on oxaliplatin avastin  
Side Effects Report: 5407594-8
106/M/x Retinal artery  
spasm
Bevacizumab  
5 mg/kg q2wk
Tunnel vision Colon cancer; obesity on oxaliplatin 
Avastin Side Effects Report: 5442353-1
Notes: Red, prospective study data; blue, literature data; black, retrospective collaborative case series; black underlined, data reported to FDA till 2009 and eHealthMe from 
FDA and community for 2010 and late 2009.
Abbreviations: AMD, wet age-related macular degeneration; DR, diabetic retinopathy; PDR, proliferative diabetic retinopathy; DM, diabetic maculopathy (in column 
of eye disease); NA, not assessed; Nl, normal; DM, diabetes mellitus (in column of systemic disease); HTN, systemic hypertension; CAD, coronary artery disease; 
CRAO, central retinal artery occlusion; BRAO, branch retinal artery occlusion; CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion; AION, 
anterior ischemic optic neuropathy; CME, cystoid macular edema; NVG, neovascular glaucoma; IOP, intraocular pressure; OD, right eye; OS, left eye; OU, bilateral; 
HM, hand motion; LP, light perception; NLP, no light perception.
no worsening of macular ischemia was found (pers comm; 
Koh HJ, March 2010).50
Evidence suggests that vessel diameter is influenced 
by the drug.51–53 Retinal arteriolar diameter decreased by 
4.6% ± 4.6% at day 7 and by 8.1% ± 3.2% at day 30 in 
eleven eyes with neovascular macular degeneration after 
treatment with intravitreal ranibizumab.51 Similarly, 1 month 
after ranibizumab was injected into ten eyes with macular 
degeneration, Mendrinos et al found a mean arterial vaso-
constriction of 8.4% ± 3.2%.52 Sacu et al found significant 
retinal arterial and venous vasoconstriction with a significant 
reduction in retinal perfusion in 27 patients with retinal 
branch vein occlusion.53 Soliman et al used bevacizumab to 
treat ten eyes with diffuse diabetic macular edema, and found 
that the most pronounced changes in vessel diameter occurred 
in two patients with proliferative diabetic retinopathy.3 We 
measured a higher vasoconstrictor effect and some eyes had 
marked vasoconstriction. It is also possible that there is a 
shift from vessel dilation driven by ischemia to constriction 
induced by VEGF antagonists, hence the large constrictive 
response which is reported.
Treatment with intravitreal VEGF antagonists is accom-
panied by exacerbation of systemic hypertension54 and attenu-
ation of systemic VEGF levels.55 This effect on the vascular 
tone may last for 3 weeks following intravitreal injections,54–56 
but Lee et al found that only 30-minute systolic values 
were significantly higher than baseline blood pressure after 
bevacizumab injection.56 It is possible that this acute rise in 
blood pressure may be related to the stress of the intravitreal 
injection. Some patients have a panic attack during the injec-
tion, others get hyperglycemia,57 while a few may develop a 
dendritic corneal ulcer following treatment.58
Transient ocular hypertension after intravitreal injec-
tion of VEGF antagonists has been emphasized in many 
studies.59–62 Persistent ocular hypertension is of recent 
concern and occurs in around 3.4% of eyes, usually fol-
lowing multiple injections.62 This may relate to the pres-
ence of silicone oil or other large particulate matter in 
the syringe, such as high molecular weight aggregates in 
repackaged bevacizumab. A considerable short-term rise 
in intraocular pressure occurs preferentially in hyperopic 
eyes60,62 and eyes with known glaucoma, so there is a need 
to monitor intraocular pressure and retinal perfusion espe-
cially in eyes with poor retinal circulation.18 Acute angle 
closure glaucoma may also be precipitated by intravitreal 
injections.62
The risk of ocular vascular events during anti-VEGF 
therapy was 0.108% in the treatments considered in the 
current study. The low rate and the large variation in 
the occurrence of such events among the collaborating 
centers may be related to several factors including the 
retrospective nature of the study, the ocular pathology 
bias, the natural history of ocular disease, and the absence 
of precisely scheduled fluorescein angiographic studies. 
Performing detailed eye examinations with fundus pho-
tography and fluorescein angiography initially, at 1 week, 
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Table 1 (Continued)
Case N./ 
sex/age
Ocular vascular  
event after
Dose used (mL) Paracentesis IOP at  
discharge  
post injection
Prior IOP Glaucoma Primary eye  
disease
Interval injection  
to detection  
of vascular 
occlusion (days)
N. prior  
injections
OD or OS Visual acuity  
prior to vascular 
event (log MAR)
Visual acuity  
after vascular  
event  
(log MAR)
Follow up  
after ocular  
event  
(months)
Systemic disease and risk of the  
vascular event per submitting  
author (new cases per total 
number of injected patients)
Miscellaneous
102/M/55 Ophthalmic artery  
occlusion
Bevacizumab 1.25 mg Yes NA NA Yes PDR/NVG 3 1 OS 20/200 (1) NLP (3.6) 3 DM, carotid artery occlusion  
1/256 bevacizumab
103/F/40 Choroidal infarction, 
HTN retinopathy
Bevacizumab  
15 mg/kg q3wk
Glioma, HTN Avastin Side Effects 
Report: 4969093-7
10424 Visual loss Bevacizumab NA NA NA NA PDR 21 NA NA NA NA DM
105/M/78 Retinal artery  
spasm
Bevacizumab  
5 mg/kg q2wk
Colon cancer on oxaliplatin avastin  
Side Effects Report: 5407594-8
106/M/x Retinal artery  
spasm
Bevacizumab  
5 mg/kg q2wk
Tunnel vision Colon cancer; obesity on oxaliplatin 
Avastin Side Effects Report: 5442353-1
Notes: Red, prospective study data; blue, literature data; black, retrospective collaborative case series; black underlined, data reported to FDA till 2009 and eHealthMe from 
FDA and community for 2010 and late 2009.
Abbreviations: AMD, wet age-related macular degeneration; DR, diabetic retinopathy; PDR, proliferative diabetic retinopathy; DM, diabetic maculopathy (in column 
of eye disease); NA, not assessed; Nl, normal; DM, diabetes mellitus (in column of systemic disease); HTN, systemic hypertension; CAD, coronary artery disease; 
CRAO, central retinal artery occlusion; BRAO, branch retinal artery occlusion; CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion; AION, 
anterior ischemic optic neuropathy; CME, cystoid macular edema; NVG, neovascular glaucoma; IOP, intraocular pressure; OD, right eye; OS, left eye; OU, bilateral; 
HM, hand motion; LP, light perception; NLP, no light perception.
and 1 month post-injection in a prospective setting (such 
as in the prospective study from Mansoura University) 
yielded higher rates of ocular events than were reported 
following retrospective quick screening examinations 
at the time of repeated injections. Many of the reported 
events were asymptomatic, such as capillary occlusion 
outside the fovea, and minor branch retinal artery or vein 
occlusion. In the RESOLVE study, a total of 102 cases 
having ranibizumab injections for diabetic maculopa-
thy resulted in two cases with retinal vascular events 
(capillary and arterial occlusions).30 In the ROCC study, 
one of the 16 patients with central retinal vein occlusion 
developed central retinal artery occlusion.63 Branch retinal 
artery occurred in one out of twelve consecutive patients 
with proliferative diabetic retinopathy following intrav-
itreal bevacizumab.32 In the ANCHOR64 and MARINA65 
studies (280 and 477 patients, respectively), no retinal 
vascular events were noted after 2 years of repeated intra-
vitreal ranibizumab for the wet form of age-related macular   
degeneration. Prior prospective studies and the current survey 
found that eyes with wet age-related macular degeneration 
had the lowest frequencies of vascular events (0%–0.3%)5,65 
while eyes with a greater number of ischemic vascular 
diseases such as proliferative diabetic retinopathy yielded 
a higher frequency of retinal vascular events (2%–19%, 
as in the current prospective study).30 The occurrence of 
ocular vascular occlusions after anti-VEGF medications 
was 2.61% in the diabetic population (Tables 1 and 2), 
almost 24 times the occurrence in the general population 
receiving VEGF antagonists (Tables 1 and 2).
Three studies show choroidal or retinal vaso-occlusion 
after intravitreal bevacizumab injections in experimental 
animals. Peters et al analyzed the acute intravitreal effects 
of bevacizumab in four cynomolgus monkeys and found that 
choriocapillaris endothelial cell fenestrations were signifi-
cantly reduced, and that densely packed thrombocytes and 
leukocytes regionally occluded the choriocapillaris lumen 
of treated eyes.66 Schraermeyer et al found that bevacizumab 
immune complexes activate platelets and cause thrombo-
sis in choroidal vessels of primate eyes.67,68 Ameri et al 
evaluated the effects of intravitreal bevacizumab in a rabbit 
retinal neovascularization model. An intravitreal VEGF 
injection was administered and intravitreal bevacizumab 
was then injected at day 2 and at week 1, and it was found 
that administration of intravitreal bevacizumab at week 1 
resulted in severe capillary nonperfusion at week 2.69 Bonnin 
et al demonstrated   ocular hypoperfusion after intravitreal 
bevacizumab in humans. In 15 patients with wet age-related 
macular degeneration, mean blood flow velocities were 
measured by ultrasound imaging before, and 4 weeks after, 
a single intravitreal injection of bevacizumab. Velocities 
decreased significantly in the central retinal, temporal 
posterior ciliary, and ophthalmic arteries by 10%, 20%, 
and 20% respectively.60,70 Sacu et al found significant vaso-
constriction of retinal arteries and veins outside the area 
of nonischemic retinal branch vein occlusions as well as a 
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Table 2 Collaborative and literature review of 38 cases of ocular vascular complications of VEGF antagonists excluding bevacizumab 
(ranibizumab and pegaptanib): clinical profile
Case N./ 
sex/age
Ocular  
vascular  
event after
Dose used (mL) Paracentesis IOP at  
discharge  
post injection
Prior IOP Glaucoma Primary eye   
disease
Interval injection  
to detection  
of vascular 
occlusion (days)
N. prior  
injections
OD or OS Visual acuity  
prior to vascular 
event (log MAR)
Visual acuity  
after vascular  
event  
(log MAR)
Follow up  
after ocular  
event  
(months)
Systemic disease and risk of the  
vascular event per submitting  
author (new cases per total 
number of injected patients)
Arterial occlusion
1/M/75 CRAO Ranibizumab 0.5 mg No Nl NA No Ischemic  
CRVO
30 1 OS 20/400 (1.3) LP (3.3) 2 DM
CAD
1/2,400 anti-VEGF
1/16 ROCC study63
2/M/67 CRAO Ranibizumab 0.5 mg No 15 15 No DM 30 4 OS 20/100 (0.7) 20/400
(1.3)
12 DM
HTN
1/6,478 anti-VEGF
330 CRAO Ranibizumab NA NA NA NA DM NA NA NA NA NA 12 DM 
1/102 eyes prospective study 
(RESOLVE)
4/M/85  
(Reimao*)
CRAO Ranibizumab 0.5 mg No 38 mmHg NA Yes NVG 2d 0 OD 20/25 (0.1) 20/80 (0.6) HTN 
COPD 
ex-smoker 
bilateral carotid stenosis
5/F/81 Retinal artery  
occlusion
Ranibizumab Lucentis Side Effects Report: 
6109626-0
6/F/x Retinal artery  
occlusion
Ranibizumab 0.5 mg HTN, CAD
Lucentis Side Effects Report: 
6184843-2
7/M/84 Retinal artery  
occlusion
Ranibizumab 0.5 mg High IOP AMD Lucentis Side Effects Report: 
6210113-X
8/F/70 Retinal artery  
occlusion
Ranibizumab Lucentis Side Effects Report: 
6480905-0, 6496635-5
9/F/70 Retinal artery  
occlusion
Ranibizumab 0.5 mg Lucentis Side Effects Report: 
6207699-8
10/F/86 Retinal artery  
occlusion
Pegaptanib HTN, dyslipidemia 
Macugen Side Effects Report: 
5248582-4, 5224175-X
11/M/67 Retinal artery  
occlusion
Pegaptanib Macugen Side Effects Report: 
6108967-0
12/F/above  
60 years
Retinal artery  
occlusion
Ranibizumab AMD ,1 month 2010 events from eHealthMe drug 
outcomes from FDA and community
Venous occlusion
13/M/84 Retinal vein  
occlusion
Ranibizumab 0.5 mg Lucentis Side Effects Report:  
5216324-4/5889807-1
14/M/74 Retinal vein  
occlusion
Ranibizumab Lucentis Side Effects Report:  
5253885-3/5259058-2
Retinal vascular occlusion (unspecified)
1537c Ocular vascular  
occlusion
Ranibizumab 0.5 mg NA NA NA NA DM NA NA NA NA NA DM
1/375 for diabetic CME
1637c Ocular vascular  
occlusion
Ranibizumab 0.5 mg NA NA NA NA DM NA NA NA NA NA DM
1/375 for diabetic CME
1737c Ocular vascular  
occlusion
Ranibizumab 0.5 mg NA NA NA NA DM NA NA NA NA NA DM
1/375 for diabetic CME
18/M/47 Retinal vascular  
disorder
Ranibizumab 0.3 mg CME Lucentis Side Effects Report:  
5896098-4
19/M/x Retinal vascular  
disorder
Ranibizumab Lucentis Side Effects Report:  
6180863-2
20/F/66 Retinal vascular  
disorder
Pegaptanib AMD Macugen Side Effects Report:  
6409650-4
(Continued)
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Table 2 Collaborative and literature review of 38 cases of ocular vascular complications of VEGF antagonists excluding bevacizumab 
(ranibizumab and pegaptanib): clinical profile
Case N./ 
sex/age
Ocular  
vascular  
event after
Dose used (mL) Paracentesis IOP at  
discharge  
post injection
Prior IOP Glaucoma Primary eye   
disease
Interval injection  
to detection  
of vascular 
occlusion (days)
N. prior  
injections
OD or OS Visual acuity  
prior to vascular 
event (log MAR)
Visual acuity  
after vascular  
event  
(log MAR)
Follow up  
after ocular  
event  
(months)
Systemic disease and risk of the  
vascular event per submitting  
author (new cases per total 
number of injected patients)
Arterial occlusion
1/M/75 CRAO Ranibizumab 0.5 mg No Nl NA No Ischemic  
CRVO
30 1 OS 20/400 (1.3) LP (3.3) 2 DM
CAD
1/2,400 anti-VEGF
1/16 ROCC study63
2/M/67 CRAO Ranibizumab 0.5 mg No 15 15 No DM 30 4 OS 20/100 (0.7) 20/400
(1.3)
12 DM
HTN
1/6,478 anti-VEGF
330 CRAO Ranibizumab NA NA NA NA DM NA NA NA NA NA 12 DM 
1/102 eyes prospective study 
(RESOLVE)
4/M/85  
(Reimao*)
CRAO Ranibizumab 0.5 mg No 38 mmHg NA Yes NVG 2d 0 OD 20/25 (0.1) 20/80 (0.6) HTN 
COPD 
ex-smoker 
bilateral carotid stenosis
5/F/81 Retinal artery  
occlusion
Ranibizumab Lucentis Side Effects Report: 
6109626-0
6/F/x Retinal artery  
occlusion
Ranibizumab 0.5 mg HTN, CAD
Lucentis Side Effects Report: 
6184843-2
7/M/84 Retinal artery  
occlusion
Ranibizumab 0.5 mg High IOP AMD Lucentis Side Effects Report: 
6210113-X
8/F/70 Retinal artery  
occlusion
Ranibizumab Lucentis Side Effects Report: 
6480905-0, 6496635-5
9/F/70 Retinal artery  
occlusion
Ranibizumab 0.5 mg Lucentis Side Effects Report: 
6207699-8
10/F/86 Retinal artery  
occlusion
Pegaptanib HTN, dyslipidemia 
Macugen Side Effects Report: 
5248582-4, 5224175-X
11/M/67 Retinal artery  
occlusion
Pegaptanib Macugen Side Effects Report: 
6108967-0
12/F/above  
60 years
Retinal artery  
occlusion
Ranibizumab AMD ,1 month 2010 events from eHealthMe drug 
outcomes from FDA and community
Venous occlusion
13/M/84 Retinal vein  
occlusion
Ranibizumab 0.5 mg Lucentis Side Effects Report:  
5216324-4/5889807-1
14/M/74 Retinal vein  
occlusion
Ranibizumab Lucentis Side Effects Report:  
5253885-3/5259058-2
Retinal vascular occlusion (unspecified)
1537c Ocular vascular  
occlusion
Ranibizumab 0.5 mg NA NA NA NA DM NA NA NA NA NA DM
1/375 for diabetic CME
1637c Ocular vascular  
occlusion
Ranibizumab 0.5 mg NA NA NA NA DM NA NA NA NA NA DM
1/375 for diabetic CME
1737c Ocular vascular  
occlusion
Ranibizumab 0.5 mg NA NA NA NA DM NA NA NA NA NA DM
1/375 for diabetic CME
18/M/47 Retinal vascular  
disorder
Ranibizumab 0.3 mg CME Lucentis Side Effects Report:  
5896098-4
19/M/x Retinal vascular  
disorder
Ranibizumab Lucentis Side Effects Report:  
6180863-2
20/F/66 Retinal vascular  
disorder
Pegaptanib AMD Macugen Side Effects Report:  
6409650-4
(Continued)
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Table 2 (Continued)
Case N./ 
sex/age
Ocular  
vascular  
event after
Dose used (mL) Paracentesis IOP at  
discharge  
post injection
Prior IOP Glaucoma Primary eye   
disease
Interval injection  
to detection  
of vascular 
occlusion (days)
N. prior  
injections
OD or OS Visual acuity  
prior to vascular 
event (log MAR)
Visual acuity  
after vascular  
event  
(log MAR)
Follow up  
after ocular  
event  
(months)
Systemic disease and risk of the  
vascular event per submitting  
author (new cases per total 
number of injected patients)
21/M/60 Retinal vascular  
disorder
Pegaptanib 0.3 mg AMD Macugen Side Effects Report:  
6463543-5
22/Above 60 years Retinal vascular  
disorder
Pegaptanib AMD Late 2009 events from eHealthMe  
drug outcomes from FDA and  
community
23–28/6 cases  
above 60 years
Retinal vascular  
disorder
Ranibizumab mixed 2010 events from eHealthMe drug  
outcomes from FDA and community
Optic neuropathy
29/M/75 AION Ranibizumab 0.5 mg AMD 4 OS 20/40 20/60 1 HTN, hypothyroidism, BPH, angina,  
on amlodipine, levothyroxine,  
temazepam, nitroglycerin
1/4500 antiVEGF injection
30/F/7037a AION OU Pegaptanib No NA NA No AMD OD
Diabetic 
prophylaxis 
for cataract 
surgery OS
7d OD
4d OS
0 OD
OS
20/40 (0.3)
NA
20/4000 (2.2)
20/200 (1)
3
3
DM
HTN
31/M/93 AION 0.3 mg Pegaptanib Visual acuity  
reduced
Macugen Side Effects Report:  
4825003-4
32/M/72 AION Pegaptanib AMD Macugen Side Effects Report:  
4982605-2
Capillary occlusion
33/F/x Retinal ischemia  
(macular)
Ranibizumab Lucentis Side Effects Report:  
5889807-1
34/F/x Retinal ischemia  
(macular)
Ranibizumab 0.5 mg Lucentis Side Effects Report:  
6454819-6
3530 Capillary occlusion  
(peripheral)
Ranibizumab NA NA NA NA DM NA NA NA NA NA 12 DM 1/102 eyes prospective study  
(RESOLVE)
36/F/x Retinal ischemia  
(peripheral)
Ranibizumab 0.5 mg 9 Lucentis Side Effects Report:  
6037721-3; patient died  
9 months after injection
37/above 60 years Retinal ischemia Ranibizumab Unspecified 2010 events from eHealthMe drug  
outcomes from FDA and community
Miscellaneous
38/M/85 Diffuse vascular  
occlusion
Ranibizumab 0.5 mg No NA 15 No Ocular  
ischemic  
syndrome
14 1 OD 20/100 (0.7) LP (3.3) 10 Carotid stenosis
Notes: Red, prospective study data; blue, literature data; black, retrospective collaborative case series; black underlined, data reported to FDA till 2009 and eHealthMe 
from FDA and community for 2010 and late 2009; *Reimao reference refers to eposter EP-GLA-405 SOE 2011 Geneve presented by Reimao P, Macedo M, Gomes M, Maia 
S, Santos M, Meneres MJ, from Portugal.
Abbreviations: AMD, wet age-related macular degeneration; DR, diabetic retinopathy; PDR, proliferative diabetic retinopathy; DM, diabetic maculopathy (in column of eye 
disease); NA, not assessed; Nl, normal; DM, diabetes mellitus; HTN, systemic hypertension; CAD, coronary artery disease; CRAO, central retinal artery occlusion; BRAO, 
branch retinal artery occlusion; CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion; AION, anterior ischemic optic neuropathy; IOP, intraocular 
pressure; OD, right eye; OS, left eye; CME, cystoid macular edema; NVG, neovascular glaucoma.
significant reduction in the flow velocity of the retrobulbar 
central retinal artery.53
The vascular events reported during VEGF antagonist 
therapies could be part of the natural history of the   underlying 
ocular disease. A rise in blood pressure, stress of the proce-
dure, the underlying systemic disease, and a sharp rise in 
intraocular pressure are variables that can be involved in some 
cases of ocular vascular events, and these variables can be 
detected and treated. A majority of the patients discussed in 
the current study had systemic diseases, particularly diabe-
tes mellitus. VEGF antagonism could play a leader role in 
some cases that demonstrated vasoconstriction by analysis 
of vessel caliber. VEGF acts as a vessel dilator by stimulat-
ing nitric oxide synthesis, and influences the autoregulation 
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Table 2 (Continued)
Case N./ 
sex/age
Ocular  
vascular  
event after
Dose used (mL) Paracentesis IOP at  
discharge  
post injection
Prior IOP Glaucoma Primary eye   
disease
Interval injection  
to detection  
of vascular 
occlusion (days)
N. prior  
injections
OD or OS Visual acuity  
prior to vascular 
event (log MAR)
Visual acuity  
after vascular  
event  
(log MAR)
Follow up  
after ocular  
event  
(months)
Systemic disease and risk of the  
vascular event per submitting  
author (new cases per total 
number of injected patients)
21/M/60 Retinal vascular  
disorder
Pegaptanib 0.3 mg AMD Macugen Side Effects Report:  
6463543-5
22/Above 60 years Retinal vascular  
disorder
Pegaptanib AMD Late 2009 events from eHealthMe  
drug outcomes from FDA and  
community
23–28/6 cases  
above 60 years
Retinal vascular  
disorder
Ranibizumab mixed 2010 events from eHealthMe drug  
outcomes from FDA and community
Optic neuropathy
29/M/75 AION Ranibizumab 0.5 mg AMD 4 OS 20/40 20/60 1 HTN, hypothyroidism, BPH, angina,  
on amlodipine, levothyroxine,  
temazepam, nitroglycerin
1/4500 antiVEGF injection
30/F/7037a AION OU Pegaptanib No NA NA No AMD OD
Diabetic 
prophylaxis 
for cataract 
surgery OS
7d OD
4d OS
0 OD
OS
20/40 (0.3)
NA
20/4000 (2.2)
20/200 (1)
3
3
DM
HTN
31/M/93 AION 0.3 mg Pegaptanib Visual acuity  
reduced
Macugen Side Effects Report:  
4825003-4
32/M/72 AION Pegaptanib AMD Macugen Side Effects Report:  
4982605-2
Capillary occlusion
33/F/x Retinal ischemia  
(macular)
Ranibizumab Lucentis Side Effects Report:  
5889807-1
34/F/x Retinal ischemia  
(macular)
Ranibizumab 0.5 mg Lucentis Side Effects Report:  
6454819-6
3530 Capillary occlusion  
(peripheral)
Ranibizumab NA NA NA NA DM NA NA NA NA NA 12 DM 1/102 eyes prospective study  
(RESOLVE)
36/F/x Retinal ischemia  
(peripheral)
Ranibizumab 0.5 mg 9 Lucentis Side Effects Report:  
6037721-3; patient died  
9 months after injection
37/above 60 years Retinal ischemia Ranibizumab Unspecified 2010 events from eHealthMe drug  
outcomes from FDA and community
Miscellaneous
38/M/85 Diffuse vascular  
occlusion
Ranibizumab 0.5 mg No NA 15 No Ocular  
ischemic  
syndrome
14 1 OD 20/100 (0.7) LP (3.3) 10 Carotid stenosis
Notes: Red, prospective study data; blue, literature data; black, retrospective collaborative case series; black underlined, data reported to FDA till 2009 and eHealthMe 
from FDA and community for 2010 and late 2009; *Reimao reference refers to eposter EP-GLA-405 SOE 2011 Geneve presented by Reimao P, Macedo M, Gomes M, Maia 
S, Santos M, Meneres MJ, from Portugal.
Abbreviations: AMD, wet age-related macular degeneration; DR, diabetic retinopathy; PDR, proliferative diabetic retinopathy; DM, diabetic maculopathy (in column of eye 
disease); NA, not assessed; Nl, normal; DM, diabetes mellitus; HTN, systemic hypertension; CAD, coronary artery disease; CRAO, central retinal artery occlusion; BRAO, 
branch retinal artery occlusion; CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion; AION, anterior ischemic optic neuropathy; IOP, intraocular 
pressure; OD, right eye; OS, left eye; CME, cystoid macular edema; NVG, neovascular glaucoma.
in the microcirculation. If we block this rescuer, the retina 
may be damaged due to decreased retinal perfusion in the 
presence of a low ophthalmic systolic pressure. Because 
retinal vessel diameter is a useful surrogate for retinal per-
fusion, changes in the diameter of the retinal arterioles may 
indicate changes in retinal capillary blood flow. Thus, these 
findings suggest that VEGF antagonists may reduce retinal 
capillary blood flow, and caution should be exercised in 
the use of intravitreal VEGF inhibitors in eyes with severe 
ocular ischemia such as ocular ischemic syndrome with low 
ophthalmic systolic pressure or severe proliferative diabetic 
retinopathy.11,15 Further studies are needed to evaluate the 
incidence of vascular events during VEGF antagonist therapy 
in such high-risk patients.11
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